In addition, insulin-dependent diabetes occurred in nearly 1% of solid cancer patients treated with anti-PD-1/PD-L1 antibodies, of which 40% had at least one positive auto-antibody and 21% had two or more, including glutamic acid decarboxylase (GAD65), islet antigen2 (IA-2/ICA-512), zinc transporter8 (ZnT8) and insulin autoantibodies (IAA) (159) (Figure 2). The gene discussed is PTPRN; the disease is type 1 diabetes mellitus.